News Kadcyla finally gets OK after price cut and NICE concessions Roche’s breast cancer drug Kadcyla is set for regular NHS funding in England after the company finally agreed a deal with NICE.
News Puma gains as Roche breast cancer combo disappoints ASCO serves up shock as Roche's data disappoints
News ASCO round up: Zytiga shines in frontline prostate role, Lox... While ASCO often showcases the benefits of new cancer therapies, it was a well-established drug that proved to be a talking point at this year’s conference in Chicago.
News AZ highlights data from next-gen oncology drugs at ASCO Tesara and Takeda among other companies to publish data.
News FDA advisers back Puma breast cancer drug despite safety wor... But biotech still has several hurdles to clear - including Roche's rival.
News Waiting on NICE decision, Pfizer provides breast cancer drug... NICE rejected Ibrance in initial decision in February.
News GBL joins CVC in €10.7bn takeover bid for Recordati A consortium of investors has made a €10.7bn offer to take Italian pharma Recordati private, but some analysts are sceptical the deal will go through.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
